Introduction

S
taphylococcus aureus, including methicillin-resistant isolates (MRSA), remains a leading cause of human bacterial infections in the European Union (EU), USA, and other parts of the world. 15, 18, 19 Moreover, MRSA infections account for 44% of hospital-acquired infections (HAI) among institutions of the EU member States, Iceland, and Norway. 19 Recent reports have demonstrated that the incidence of invasive diseases caused by MRSA has been in decline in England, 21 as well as in USA 6, 16, 17, 37 and Canada. 39 These changes in the incidence of MRSA infections are still poorly understood; but it is clear that the epidemiology of MRSA causing communityacquired infections and HAI continues to evolve in the Americas, Europe, and elsewhere. 1, 2, 4, 9, 11, 13, 32 The usual high rates of MRSA infections and the attributable mortality and costs associated with these infections have prompted the development of new anti-gram-positive agents, including ceftobiprole. 19 Ceftobiprole is a novel and broad-spectrum cephalosporin for intravenous administration. This agent has demonstrated an anti-MRSA activity due to its high affinity for the S. aureus penicillin-binding protein 2a (PBP2a) as well as the normal complement of b-lactam-sensitive PBPs. Ceftobiprole has also shown in vitro activity against the common bacterial pathogens causing pneumonia, including Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae, and noncarbapenemase expressing extended-spectrum b-lactamasenegative Klebsiella pneumoniae and Pseudomonas spp. 5, 14, 38 In Phase 3 trials for skin and soft tissue infections, ceftobiprole demonstrated noninferiority compared to vancomycin. 29, 30 Ceftobiprole has also proven noninferiority to ceftriaxone with or without linezolid for the treatment of community-acquired pneumonia (CAP) requiring hospitalization in Phase 3 trials, with overall cure rates in the clinically evaluable population of 86.6% for ceftobiprole and 87.4% for the comparator agents. 28 In a Phase 3 trial for the treatment of nosocomial pneumonia (NP), ceftobiprole achieved noninferiority when compared to ceftazidime plus linezolid (cure in clinically evaluable patients of 77% for ceftobiprole and 76% for combination therapy). In this same study, ceftobiprole was not as effective as ceftazidime in the subgroup of patients with ventilator-associated pneumonia (VAP). 3 The objectives of this study were to characterize the MRSA isolates responsible for NP and CAP infections collected during Phase 3 clinical trials for ceftobiprole.
Materials and Methods
Clinical isolates
A total of 121 S. aureus isolates from 91 subjects collected during the pneumonia clinical trials were forwarded to JMI Laboratories for further characterization. These isolates were part of the study numbers BAP00248/307 (hospitalacquired pneumonia) (119 strains) and from CAP-3001 (hospitalized patients with CAP) (two strains), and were recovered between July 2005 and April 2007. Twenty of the patients had multiple isolates, but only one isolate per patient was included in the analysis presented here and these strains were all recovered at the first study visit, except for five strains collected during follow-up study visits (1-3 days after study enrollment). Finally, 84 (54 and 28 from NP and VAP infections, respectively) and two (CAP) isolates from studies BAP00248/307 and CAP-3001, respectively, were part of the analysis. The isolates included in this study were recovered from hospitalized patients in Europe (42/84; 50.0%), Asia-Western Pacific region (17/84; 20.2%), North America (16/84; 19.0%), Latin America (7/84; 8.3%), and South Africa (2/84; 2.4%).
SCCmec typing and detection of PVL genes
SCCmec types (I through VI) were characterized using a multiplex polymerase chain reaction (PCR) strategy. 25, 31 Panton-Valentine leukocidin (PVL) (lukF-PV and lukS-PV) screening was performed by using multiplex real-time (RT)-PCR assays, as previously described. 20 Epidemiologic typing of MRSA Chromosomal DNA was subjected to pulsed-field gel electrophoresis (PFGE) after digestion with SmaI. 22 Gel pattern analysis was performed using the GelCompar II software (Applied Math) and the patterns obtained compared to those of the major USA and international clones, which were provided by the Network on Antimicrobial Resistance in S. aureus (NARSA, www.narsa.net). All strains were subjected to agr and spa typing. 34, 36 Clonal complexes (CCs) were assigned based on the spa and/or multilocus sequence typing (MLST) results. 24, 33 MRSA strains with spa typing results previously associated with specific MLST in the MLST-mapping database (http://spa.ridom.de/mlst) or peerreviewed publications had the CCs assigned accordingly. 24 Strains with new spa typing denominations and unknown MLST associations, but clustering within PFGE types containing strains with known CC results, were assigned the same CCs. MLST was performed in a given strain when showing spa type with unknown MLST association and a unique PFGE type.
Susceptibility testing
Isolates were tested for susceptibility at a central laboratory facility by broth microdilution according to the Clinical and Laboratory Standards Institute (CLSI) M07-A9 document. 7 Validation of the minimum inhibitory concentration (MIC) values was performed by concurrent testing of CLSI-recommended quality control reference strains (S. aureus ATCC 29213, and Enterococcus faecalis ATCC 29212). 8 Interpretive breakpoints (susceptible £2 mg/ml and resistant >2 mg/ml) utilized for ceftobiprole when tested against S. aureus were as approved by the European Committee on Antimicrobial Susceptibility Testing 12 and described in the Zevtera Ò Summary of Product Characteristics 23 ; and the pharmacokinetics/pharmacodynamics (PK/PD) breakpoint (susceptible £4 mg/ml and resistant >4 mg/ml) established based on 500 mg administered as a 2-hr intravenous infusion every 8 hr. 27 Results and Discussions Table 1 lists the overall distribution of MRSA clones detected in this study and the majority of isolates were CC5-MRSA-I/II/IV (44.0%; 37/84), which were followed by CC8-MRSA-IV (22.6%; 19/84) and CC239-MRSA-III (21.4%; 18/84). The remaining isolates formed seven clusters with one to three isolates per clonal type. The majority (68.8%; 11/16) of clinical trial strains collected from North America were CC5-MRSA-II/IV and agr 2 ( Table 2) . These CC5-MRSA-II/IV isolates grouped within the PFGE NA-D or -G, and the former pattern matched that of USA100 or Canadian MRSA-2. 22 A single CC5-MRSA-IV isolate from USA also clustering within NA-D harbored a SCCmec type IV, which has been designated as the pediatric clone. 26 Three CC8-MRSA-IV isolates from three different sites harbored agr operon type 1 and were PVL-positive. These 
a Three PVL-positive strains from the United States and displaying PFGE patterns similar to USA300. One isolate was associated with CAP.
b One isolate was associated with CAP. CC, Clonal complex; CAP, community-acquired pneumonia; PFGE, pulsed-field gel electrophoresis; PVL, Panton-Valentine leukocidin.
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strains demonstrated PFGE profiles (NA-C) that matched that of USA300, 22 and one isolate was obtained from a CAP infection. One strain each of CC45-MRSA-II and CC12-MRSA-IV was detected in subjects from USA. CC45-MRSA-II displayed a unique PFGE pattern (NA-B), which matched that of USA600 ( Table 2 ). Of note, CC8-MRSA-IV (agr 1) isolates were mostly from Russia (87.5%; 14/16) and one strain each from Ukraine and Lithuania. These strains clustered within six PFGE types belonging to a single spa type (t008), except for one strain having a t008 variant (t2032) ( Table 2) . Isolates belonging to CC239-MRSA-III (PFGE types EU-D and -E), also known as the Brazilian/ Hungarian clone, 26 were observed in Romania (80.0%; 8/ 10) or Serbia and Montenegro (20.0%; 2/10), while CC5-MRSA-II strains (t002/t003; agr 2) were detected in Germany (two strains), Hungary (four strains), and Israel (one (17) Australia (1) Table 2 ). Overall, strains from the APAC region were either CC5-MRSA-II (47.1%; 8/17) or CC239-MRSA-III (47.1%; 8/17), except for a single strain from Korea, which was CC8-MRSA-IV (Table 2 ). CC5 strains were collected from Korea, except for one strain from Taiwan, whereas CC239 was noted from Australia (one isolate), Taiwan (two isolates), Thailand (two isolates), and China (three isolates). One CC239 isolate was associated with CAP. All isolates recovered from Latin America were CC5-MRSA-I (85.7%; 6/7) or -II (14.3%; 1/7). CC5-MRSA-I strains (Argentina) belonged to PFGE LA-B or -C and the LA-B profile was associated with the prevalent Cordobes/Chilean clone. 35 A single CC5-MRSA-II (Brazil) strain displayed a PFGE pattern similar to that of the USA100 prototype (Table 2) . 22 Two baseline isolates recovered from a subject in South Africa were CC30-MRSA-II (agr 3) and showed a PFGE profile similar to the isolate from the United Kingdom (USA200 or UK-eMRSA-16) described in Table 2. 22 Table 3 shows the distribution of each clonal type between study arms. Overall, there were only minor differences noted between treatment arms (Table 3) . One exception was observed for the CC239-MRSA-III lineage, which was more common in the comparator drug arm (25.5%) than in the ceftobiprole treatment arm (16.2%). However, the difference was not statistically significant ( p-value (0.107) ( Table 3) . Ceftobiprole inhibited 96.4% of baseline MRSA isolates at the breakpoint for susceptibility (i.e., £2 mg/ml) and showed MIC 50 and MIC 90 values of 1 and 2 mg/ml, respectively. Moreover, higher ceftobiprole MIC 50 values (i.e., 2 mg/ml) were observed for isolates carrying SCCmec I and III, while those MRSA with SCCmec II and IV had MIC 50 values of 1 mg/ml (Table 4 ). Similar observations were previously reported by Farrell et al.
14 and Davies et al. The most common clonal types observed among isolates collected from the patients enrolled in the pneumonia Phase 3 clinical trials for ceftobiprole belonged to CC5-MRSA-I/ II/IV (44.0%; 37/84), CC8-MRSA-IV (22.6%; 19/84), and CC239-MRSA-III (21.4%; 18/84). Similar results were reported among MRSA baseline isolates collected in a worldwide pneumonia clinical trial for linezolid, where CC5, CC8, and CC239 constituted 56.0, 23.3, and 11.3% of the isolates, respectively. 24 Of note, although isolates belonging to CC8-MRSA-IV (38.1%) prevailed, the MRSA population in European countries and Israel demonstrated a greater genetic diversity than observed in other regions. The CC8-MRSA-IV lineage seems to be replacing previous commonly detected MRSA clones in this region, such as ST247-MRSA-I (Iberian; CC8), ST228-MRSA-I (South German; CC5), ST239-MRSA-III (CC239; Brazilian/Hungarian), CC22-MRSA-IV (UK-eMRSA-15), and ST45-MRSA-IV (CC45; Berlin). However, one significant study limitation is the relatively low number of baseline pathogens, which precludes a more robust statistical analysis. In summary, the isolates included in the present study were found to represent common clones currently circulating in these study regions and ceftobiprole demonstrated a slight variation in the MIC results according to SCCmec or clonal type, but overall inhibited 96.4% and 100.0% of isolates at £2 and £4 mg/ml, respectively. 27 
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